Have a feature idea you'd love to see implemented?
Let us know!
AVTE Aerovate Therapeutics Inc
Price (delayed)
$2.1
Market cap
$60.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.14
Enterprise value
$30.23M
Highlights
AVTE's debt is down by 20% YoY and by 12% from the previous quarter
The company's equity fell by 33% YoY but it rose by 3.8% QoQ
The quick ratio has contracted by 46% YoY and by 4.4% from the previous quarter
The net income has declined by 37% year-on-year and by 7% since the previous quarter
Key stats
What are the main financial stats of AVTE
Market
Valuations
Earnings
Shares outstanding
28.87M
Market cap
$60.62M
Enterprise value
$30.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$87.88M
EBITDA
-$87.77M
Free cash flow
-$74.61M
Per share
Balance sheet
Liquidity
EPS
-$3.14
Free cash flow per share
-$2.59
Book value per share
$3.28
Revenue per share
$0
TBVPS
$3.88
Total assets
$111.69M
Total liabilities
$17.3M
Debt
$681,000
Equity
$94.4M
Working capital
$93.74M
Debt to equity
0.01
Current ratio
6.51
Quick ratio
6.12
Net debt/EBITDA
0.35
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-72.3%
Return on equity
-83.7%
Return on invested capital
-106.9%
Return on capital employed
-92.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVTE stock price
How has the Aerovate Therapeutics stock price performed over time
Intraday
-4.55%
1 week
-9.48%
1 month
7.42%
1 year
-81.17%
YTD
-90.72%
QTD
0.48%
Financial performance
How have Aerovate Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$94.22M
Net income
-$87.94M
Gross margin
N/A
Net margin
N/A
AVTE's operating income is down by 39% year-on-year and by 7% since the previous quarter
The net income has declined by 37% year-on-year and by 7% since the previous quarter
Growth
What is Aerovate Therapeutics's growth rate over time
Valuation
What is Aerovate Therapeutics stock price valuation
P/E
N/A
P/B
0.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
AVTE's EPS is down by 21% year-on-year and by 3.3% since the previous quarter
The price to book (P/B) is 86% less than the last 4 quarters average of 4.6
The company's equity fell by 33% YoY but it rose by 3.8% QoQ
Efficiency
How efficient is Aerovate Therapeutics business performance
The return on equity has dropped by 70% year-on-year and by 19% since the previous quarter
The company's return on invested capital has shrunk by 65% YoY and by 13% QoQ
The return on assets has dropped by 59% year-on-year and by 17% since the previous quarter
Dividends
What is AVTE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVTE.
Financial health
How did Aerovate Therapeutics financials performed over time
The quick ratio has contracted by 46% YoY and by 4.4% from the previous quarter
Aerovate Therapeutics's current ratio has decreased by 43% YoY and by 2.1% from the previous quarter
AVTE's debt is 99% less than its equity
The company's equity fell by 33% YoY but it rose by 3.8% QoQ
AVTE's debt is down by 20% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.